| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047642803 |
| P356 | DOI | 10.1007/S11060-010-0297-3 |
| P8608 | Fatcat ID | release_twf7twmhtvelvmjh3pow5qndmy |
| P932 | PMC publication ID | 2954435 |
| P698 | PubMed publication ID | 20607350 |
| P5875 | ResearchGate publication ID | 45098289 |
| P50 | author | Peter C. Burger | Q105958300 |
| P2093 | author name string | Children's Oncology Group | |
| Daniel J Brat | |||
| Marina N Nikiforova | |||
| Marc K Rosenblum | |||
| Ronald L Hamilton | |||
| Ian F Pollack | |||
| Regina I Jakacki | |||
| Kenneth J Cohen | |||
| Tianni Zhou | |||
| Emiko J Holmes | |||
| Geoffrey H Murdoch | |||
| P2860 | cites work | Tyrosine kinase expression in pediatric high grade astrocytoma | Q46809466 |
| Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. | Q48221611 | ||
| Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort | Q48258630 | ||
| Subsets of glioblastoma multiforme defined by molecular genetic analysis | Q48379049 | ||
| Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas | Q48475005 | ||
| Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. | Q48675680 | ||
| Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas | Q48972634 | ||
| Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. | Q51992670 | ||
| Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. | Q53594703 | ||
| PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. | Q55469269 | ||
| Expression of p53 and prognosis in children with malignant gliomas. | Q55473725 | ||
| PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. | Q55474170 | ||
| Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. | Q55476168 | ||
| Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. | Q55476256 | ||
| Genetic alterations in pediatric high-grade astrocytomas. | Q55476452 | ||
| An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53 | Q67539546 | ||
| Brain tumors in children | Q72827847 | ||
| NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures | Q26778382 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B | Q27860731 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Regulation of cell death protease caspase-9 by phosphorylation | Q28288607 | ||
| Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections | Q33263235 | ||
| Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma | Q33370229 | ||
| Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies | Q33644407 | ||
| Progression as exemplified by human astrocytic tumors | Q33711319 | ||
| Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas | Q34191508 | ||
| Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort | Q34642166 | ||
| The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience | Q35158360 | ||
| Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients | Q36644036 | ||
| Incidence, mechanism and prognostic value of activated AKT in pancreas cancer | Q36648105 | ||
| A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma | Q37003323 | ||
| Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy | Q37367106 | ||
| Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer | Q38457067 | ||
| Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. | Q38459342 | ||
| Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood | Q38467726 | ||
| Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. | Q39960673 | ||
| A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity | Q40028705 | ||
| Activation of Akt predicts poor outcome in neuroblastoma | Q40181645 | ||
| Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells | Q40243368 | ||
| Determinants of rapamycin sensitivity in breast cancer cells | Q40590648 | ||
| AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression | Q40623520 | ||
| Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. | Q40744582 | ||
| Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas | Q40769882 | ||
| Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma | Q42013793 | ||
| Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival | Q45867094 | ||
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study | Q46585156 | ||
| Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity | Q46670127 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 155-163 | |
| P577 | publication date | 2010-07-04 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group | |
| P478 | volume | 99 |
| Q33764664 | A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors |
| Q30870633 | Advances in the management of paediatric high-grade glioma |
| Q34217883 | Aplasia Ras homologue member I overexpression induces apoptosis through inhibition of survival pathways in human hepatocellular carcinoma cells in culture and in xenograft |
| Q36844744 | Biologically targeted therapeutics in pediatric brain tumors |
| Q39415249 | Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. |
| Q55462828 | Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. |
| Q39197715 | Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma |
| Q35070545 | Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. |
| Q36997815 | Isoform level expression profiles provide better cancer signatures than gene level expression profiles |
| Q26785952 | Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment |
| Q38070437 | Molecular diagnostics in paediatric glial tumours |
| Q55349951 | Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. |
| Q38873292 | Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials. |
| Q36179171 | PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome |
| Q36644898 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy |
| Q39208269 | Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. |
| Q38035070 | Pediatric neuro-oncology: current status and future directions. |
| Q54286593 | Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. |
| Q38203283 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment |
| Q91195524 | Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children |
| Q28070264 | The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors |
| Q37904503 | Treatment of high-grade glioma in children and adolescents |
| Q37708428 | Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience |
Search more.